Hormone receptor–positive, HER2-negative metastatic breast cancer: redrawing the lines

Current oncology

C. Brezden-Masley¹  S. Verma³  S. Chia⁴  A. Matutino⁶  A.A. Joy⁷ 

[1] Cross Cancer Institute;University of Calgary;BC Cancer;St. Michael’s Hospital;Tom Baker Cancer Centre;Tom Baker Cancer Centre, University of Calgary;University of Alberta

关键词: Antineoplastic agents;    hormonal therapy;    combined chemotherapy protocols;    breast neoplasms;    drug therapy;    metastasis;   

DOI  :  10.3747/co.25.4000

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Estrogen receptor modulators and estrogen deprivation have become standards of care for hormone receptor– positive metastatic breast cancer. However, after traditional first-line endocrine monotherapy treatment, the disease typically progresses despite the initial high rate of clinical benefit. Multiple studies have aimed at optimizing treatment strategies to improve upon clinical benefit beyond the traditional single-agent endocrine treatment. With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit. In this review, we present treatment options clinically relevant to the management of hormone-positive, her2-negative metastatic breast cancer, and we propose a treatment algorithm based on the current literature.

【 授权许可】

Unknown